QLGN Qualigen Therapeutics Inc.

4.1
-0.47  -10%
Previous Close 4.57
Open 4.35
52 Week Low 3.71
52 Week High 30.75
Market Cap $51,414,000
Shares 12,540,000
Float 12,540,000
Enterprise Value $57,307,800
Volume 2,446,808
Av. Daily Volume 1,774,464
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
RP-G28
Lactose intolerance
Phase 3
Phase 3
Phase 3 data failed to meet primary endpoint - September 12, 2019.

Latest News

  1. CARLSBAD, Calif., July 1, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the "Company") announces it has submitted an official notification to the U.S. Food and Drug Administration ("FDA") to commence sales in the U.S. of the Company's FastPack® SARS-CoV-2 IgG test for COVID-19 antibodies.  This test has already been submitted to the FDA for Emergency Use Authorization ("EUA"), but the notification enables Qualigen to commence sales even before the FDA considers or formally grants the EUA for the test.  Qualigen expects sales and shipments of the new test to begin in mid-July.

    The FastPack® COVID-19 antibody test is a chemiluminescent microparticle test intended for the qualitative detection (i.e., yes/no) of SARS-CoV-2…

    CARLSBAD, Calif., July 1, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the "Company") announces it has submitted an official notification to the U.S. Food and Drug Administration ("FDA") to commence sales in the U.S. of the Company's FastPack® SARS-CoV-2 IgG test for COVID-19 antibodies.  This test has already been submitted to the FDA for Emergency Use Authorization ("EUA"), but the notification enables Qualigen to commence sales even before the FDA considers or formally grants the EUA for the test.  Qualigen expects sales and shipments of the new test to begin in mid-July.

    The FastPack® COVID-19 antibody test is a chemiluminescent microparticle test intended for the qualitative detection (i.e., yes/no) of SARS-CoV-2 IgG antibodies in blood to identify individuals with an adaptive immune response to the virus that causes COVID-19, indicating recent or prior infection of the disease (which, as a practical matter, is believed to be indicative of immunity against re-infection).  Qualigen's FastPack® test uses a specific protein that is also used by major diagnostics companies including Abbott Laboratories, Roche Diagnostics and Bio-Rad Laboratories in their COVID-19 antibody tests. The important advantage of FastPack® over testing in large commercial laboratories, however, is its ability to deliver accurate results far more rapidly, in this case under 10 minutes, in physician offices, clinics and hospitals. 

    "Of the different options available, we chose to develop a test specific to the IgG antibody because IgG represents the long-term immune response. We believe our test's combination of high speed and high accuracy provides the clinician with more useful and actionable information than other testing approaches," Michael Poirier, the Company's CEO, explained. "We believe that reliable, yet convenient testing at the point-of-care is critical to helping combat this virus and get Americans back to their normal routines."  

    The new test is designed for use with Qualigen's new FastPack® PRO System point-of-care diagnostic instruments. The FastPack® PRO System is an upgraded version of Qualigen's flagship FastPack® IP rapid immunoassay diagnostic point-of-care system.

    Qualigen has been producing high-quality diagnostic testing products for almost 20 years, and has established a strong reputation for delivering highly accurate point-of-care tests that help save people's lives. 

    About the FastPack® System

    The FastPack® System is a rapid and highly accurate immunoassay testing system consisting of the FastPack® Analyzer and the FastPack® test pouch (a single-use, disposable, foil packet that includes the FastPack® reagent chemistry). This "Laboratory in a Pouch" is installed in physician offices, clinics and small hospitals around the world, and quickly detects diseases and medical conditions at the point-of-care.  Since the conception of the system, the Company has expanded its assay menu to 10 tests including tests for prostate cancer, thyroid function, metabolic disorders, antibodies against SARS-CoV-2, and research applications. Over the past 20 years, FastPack® has generated more than $100 million in commercial sales.  Qualigen's worldwide distributor for FastPack® is Sekisui Diagnostics, LLC, a subsidiary of a multibillion-dollar Japanese chemical and technology company; Sekisui, in turn, works with national distributors including McKesson Corporation and Henry Schein Inc. 

    About Qualigen Therapeutics, Inc.

    Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack® System, which has been used successfully in diagnostics for almost 20 years. The FastPack® menu includes tests for cancer, men's health, hormone function, vitamin D status and antibodies against SARS-CoV-2. The Company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS™. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. The foundational aptamer of ALAN, AS1411, is also being studied for use in treating viral-based infectious diseases, including COVID-19.   RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS™ is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. Qualigen's facility in Carlsbad, California is FDA and ISO Certified and its FastPack® product line is sold worldwide by its commercial partner Sekisui Diagnostics, LLC. For more information on Qualigen Therapeutics, Inc., please visit https://www.qualigeninc.com/.  

    Qualigen Forward-Looking Statements

    This news release contains forward-looking statements by the Company that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. These statements include those related to potential future development, testing and launch of product candidates. Actual events or results may differ from our expectations. For example, there can be no assurance that the Company will be able to manufacture the FastPack® Pro System instruments and SARS-CoV-2 IgG test kits successfully; that any commercialization of the FastPack® Pro System instruments and SARS-CoV-2 IgG test kits will be profitable; that adoption and placement of FastPack® Pro System instruments (which are the only FastPack® instruments on which the Company's SARS-CoV-2 IgG test kits can be run) will be widespread; that the Company's request to the FDA for Emergency Use Authorization will ultimately be approved; that the Company will successfully develop any drugs or therapeutic devices; that preclinical or clinical development of the Company's drugs or therapeutic devices will be successful; that future clinical trial data will be favorable or that such trials will confirm any improvements over other products or lack negative impacts; that any drugs or therapeutic devices will receive required regulatory approvals or that they will be commercially successful; that we will be able to procure or earn sufficient working capital to complete the development, testing and launch of our prospective therapeutic products; or that we will be able to maintain or expand market demand and/or market share for our diagnostic products.  Our stock price could be harmed if any of the events or trends contemplated by the forward-looking statements fails to occur or is delayed or if any actual future event otherwise differs from expectations. Additional information concerning these and other risk factors affecting the Company's business (including events beyond the Company's control, such as epidemics and resulting changes) can be found in the Company's prior filings with the Securities and Exchange Commission, available at www.sec.gov.  The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

     

    Cision View original content:http://www.prnewswire.com/news-releases/qualigen-therapeutics-submits-notification-to-fda-to-commence-distribution-of-its-fastpack-covid-19-antibody-test-301086597.html

    SOURCE Qualigen, Inc.

    View Full Article Hide Full Article
  2. CARLSBAD, Calif., June 10, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (Qualigen or the Company) announced today the signing of an exclusive license agreement with the University of Louisville (UofL) to facilitate development of Qualigen's AS1411 DNA aptamer as a drug candidate for the treatment of COVID-19, the disease caused by the novel coronavirus SARS-CoV-2. 

    AS1411 targets and binds with nucleolin, a human protein utilized by some viruses to enter a cell.  Proof-of-concept in vitro studies recently performed at UofL demonstrate that by binding to nucleolin, AS1411 may protect cells from the damaging effects of SARS-CoV-2 infection.

    Qualigen has held an exclusive license to AS1411 for all fields of use since 2018…

    CARLSBAD, Calif., June 10, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (Qualigen or the Company) announced today the signing of an exclusive license agreement with the University of Louisville (UofL) to facilitate development of Qualigen's AS1411 DNA aptamer as a drug candidate for the treatment of COVID-19, the disease caused by the novel coronavirus SARS-CoV-2. 

    AS1411 targets and binds with nucleolin, a human protein utilized by some viruses to enter a cell.  Proof-of-concept in vitro studies recently performed at UofL demonstrate that by binding to nucleolin, AS1411 may protect cells from the damaging effects of SARS-CoV-2 infection.

    Qualigen has held an exclusive license to AS1411 for all fields of use since 2018.  The new agreement provides a license under UofL's pending U.S. patent for the use of AS1411 for inhibiting or treating COVID-19.  Qualigen has separately been developing ALAN (the AS1411 aptamer attached to a gold nanoparticle) as a drug candidate against cancer, under a previous technology license agreement with UofL.

    Under the new agreement, Qualigen agreed to pay UofL royalties in the low-to-mid-single-digit percentages on sales of AS1411 anti-COVID-19 products using UofL's technology or patents, and undertook to enter into a sponsored research agreement with UofL for further in vitro and preclinical animal studies with AS1411 as a drug candidate against COVID-19. In previous research, AS1411 was administered to more than 100 human cancer patients and was well tolerated with no evidence of severe side effects. 

    In addition to developing ALAN and pursuing AS1411 as an anti-COVID-19 drug, because nucleolin has been implicated in mediating the uptake, nuclear trafficking and infectiousness of many viruses, Qualigen will also seek to investigate the potential use of AS1411 as a broader spectrum antiviral therapeutic.

    "We are pleased to expand our strong working relationship with the University of Louisville and to broaden our therapeutic pipeline to include the treatment of COVID-19 with AS1411," said Michael Poirier, President, Chief Executive Officer and Chairman of Qualigen.  "As everyone knows, there is an urgent need to develop novel treatments to fight this deadly virus. We believe AS1411 is a promising approach and we look forward to working with the University of Louisville on this important program." 

    Paula Bates, PhD, Professor of Medicine at UofL, partnered with fellow researcher Kenneth Palmer, PhD, Director of the UofL Center for Predictive Medicine and Regional Biocontainment Laboratory, who conducted the proof-of-concept in vitro experiments demonstrating the aptamer was potentially effective against the SARS-CoV-2 virus at doses shown to be safe by previous research.  

    "This has been a true collaborative effort — everyone at the University of Louisville has rallied together to tackle this global health challenge," Dr. Bates added. "We are fortunate to have access to one of the few infectious disease biocontainment facilities in the country that has the ability to conduct this important work."

    About Qualigen Therapeutics, Inc.

    Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack System, which has been used successfully in diagnostics for almost 20 years. The FastPack menu includes tests for cancer, men's health, hormone function and vitamin D status. The Company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS™. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. The foundational aptamer of ALAN, AS1411, is also being studied for use in treating viral-based infectious diseases, including COVID-19.   RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. Qualigen's facility in Carlsbad, California is FDA and ISO Certified and its FastPack product line is sold worldwide by its commercial partner Sekisui Diagnostics, LLC. For more information on Qualigen Therapeutics, Inc., please visit https://www.qualigeninc.com/.   

    Qualigen Forward-Looking Statements

    This news release contains forward-looking statements by the Company that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. These statements include those related to potential future development, testing and launch of product candidates. Actual events or results may differ from our expectations. For example, there can be no assurance that the AS1411 will be safe and effective against COVID-19 or other viral infections in humans; that clinical trials will be approved to begin by, or will actually begin by, any particular date; that the Company will successfully develop any drugs or therapeutic devices; that preclinical or clinical development will be successful; that future clinical trial data will be favorable or that such trials will confirm any improvements over other products or lack negative impacts; that any drugs or therapeutic devices will receive required regulatory approvals or that they will be commercially successful; that we will be able to procure or earn sufficient working capital to complete the development, testing and launch of our prospective therapeutic products; or that we will be able to maintain or expand market demand and/or market share for our diagnostic products.  Our stock price could be harmed if any of the events or trends contemplated by the forward-looking statements fails to occur or is delayed or if any actual future event otherwise differs from expectations. Additional information concerning these and other risk factors affecting the Company's business (including events beyond the Company's control, such as epidemics and resulting changes) can be found in the Company's prior filings with the Securities and Exchange Commission, available at www.sec.gov.  The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

     

    Cision View original content:http://www.prnewswire.com/news-releases/qualigen-therapeutics-signs-exclusive-license-agreement-with-the-university-of-louisville-plans-to-develop-as1411-for-the-treatment-of-covid-19-301073447.html

    SOURCE Qualigen, Inc.

    View Full Article Hide Full Article
  3. CARLSBAD, Calif., June 4, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (Qualigen or the Company) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for a U.S. patent, which will be issued to the Company, titled "Devices and Methods for On-Line Whole Blood Treatment" regarding the Company's Selective Target Antigen Removal System (STARS™) technology. STARS is a DNA/RNA-based treatment for the removal of viral and tumor-produced compounds from a patient's blood.  The STARS technology utilizes a filtration cartridge designed for use in a standard dialysis machine, and contains aptamer-coated microparticles that bind to specific agents in circulating blood for targeted removal.

    CARLSBAD, Calif., June 4, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (Qualigen or the Company) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for a U.S. patent, which will be issued to the Company, titled "Devices and Methods for On-Line Whole Blood Treatment" regarding the Company's Selective Target Antigen Removal System (STARS™) technology. STARS is a DNA/RNA-based treatment for the removal of viral and tumor-produced compounds from a patient's blood.  The STARS technology utilizes a filtration cartridge designed for use in a standard dialysis machine, and contains aptamer-coated microparticles that bind to specific agents in circulating blood for targeted removal.

    "When issued, this new U.S. patent will further protect our proprietary STARS technology and enhance our overall intellectual property portfolio," said Michael Poirier, President, Chief Executive Officer and Chairman of Qualigen.  "Qualigen's strategy to fighting disease is to 'Detect, Destroy, Remove'.   Supporting the Remove component, the STARS development program utilizes technology and expertise from our FastPack® point-of-care diagnostic system, which has been in use worldwide for nearly 20 years for the detection of cancer and other diseases.  We look forward to advancing STARS as a target and removal therapy for multiple diseases and other health conditions."

    The Company plans to develop STARS for cancer applications to remove inflammatory factors and inhibitory checkpoints from blood, thus reducing pain and helping the body's immune system fight the disease, as well as for infectious diseases to remove viruses and other foreign agents. STARS technology and key components utilize membranes coated with target capture reagents. STARS is in the early stages of development and has demonstrated promising proof-of-concept results in the Company's in vitro studies. 

    About Qualigen Therapeutics, Inc.
    Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack System, which has been used successfully in diagnostics for almost 20 years. The FastPack menu includes tests for cancer, men's health, hormone function and vitamin D status. The Company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS™. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. The foundational aptamer of ALAN, AS1411, is also being studied for use in treating viral-based infectious diseases.   RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. Qualigen's facility in Carlsbad, California is FDA and ISO Certified and its FastPack product line is sold worldwide by its commercial partner Sekisui Diagnostics, LLC. For more information on Qualigen Therapeutics, Inc. or to order FastPack diagnostic products, please visit https://www.qualigeninc.com/.   

    Forward-Looking Statements
    This news release contains forward-looking statements by the Company that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. These statements include those related to potential future development, testing and launch of product candidates. Actual events or results may differ from our expectations. For example, there can be no assurance that the Company will successfully develop STARS or any other drugs or therapeutic devices; that preclinical or clinical development will be successful; that future clinical trial data will be favorable or that such trials will confirm any improvements over other products or lack negative impacts; that STARS or any other drugs or therapeutic devices will receive required regulatory approvals or that they will be commercially successful; that any patents could withstand validity challenges or that patent protection will successfully preclude competitive products; that we will be able to procure or earn sufficient working capital to complete the development, testing and launch of our prospective therapeutic products; or that we will be able to maintain or expand market demand and/or market share for our diagnostic products.  Our stock price could be harmed if any of the events or trends contemplated by the forward-looking statements fails to occur or is delayed or if any actual future event otherwise differs from expectations. Additional information concerning these and other risk factors affecting the Company's business (including events beyond the Company's control, such as epidemics and resulting changes) can be found in the Company's prior filings with the Securities and Exchange Commission, available at www.sec.gov.  The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

     

    Cision View original content:http://www.prnewswire.com/news-releases/qualigen-therapeutics-receives-us-patent-notice-of-allowance-for-its-stars-technology-301070543.html

    SOURCE Qualigen, Inc.

    View Full Article Hide Full Article
  4. CARLSBAD, Calif., June 2, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (Qualigen or the Company) announced today that the Company has released a pre-launch supply of its proposed FastPack® SARS-CoV-2 IgG Immunoassay diagnostic test kits to the University of Louisville to conduct validation studies with hundreds of patient samples, as well as for use in research on COVID-19.  SARS-CoV-2 is the virus that causes COVID-19.

    Qualigen's SARS-CoV-2 IgG immunoassay, for use with its new FastPack PRO System point-of-care diagnostic instruments, is a chemiluminescent microparticle test intended for the qualitative detection (i.e., yes/no) of the presence of SARS-CoV-2 IgG antibodies in blood. The FastPack PRO System is an upgraded version…

    CARLSBAD, Calif., June 2, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (Qualigen or the Company) announced today that the Company has released a pre-launch supply of its proposed FastPack® SARS-CoV-2 IgG Immunoassay diagnostic test kits to the University of Louisville to conduct validation studies with hundreds of patient samples, as well as for use in research on COVID-19.  SARS-CoV-2 is the virus that causes COVID-19.

    Qualigen's SARS-CoV-2 IgG immunoassay, for use with its new FastPack PRO System point-of-care diagnostic instruments, is a chemiluminescent microparticle test intended for the qualitative detection (i.e., yes/no) of the presence of SARS-CoV-2 IgG antibodies in blood. The FastPack PRO System is an upgraded version of Qualigen's flagship FastPack IP rapid immunoassay diagnostic point-of-care system.     

    "This is an important step in the evolution of SARS-CoV-2 antibody testing, given the high number of inaccurate tests in the marketplace," said Michael Poirier, President, Chief Executive Officer and Chairman of Qualigen.  "Reliable, accurate and rapid testing for the presence of antibodies is critical to understanding who may have been infected with SARS-CoV-2 and who could potentially have an immune response to re-infection." 

    Mr. Poirier continued, "Since its founding in my basement in Minnesota over 20 years ago, Qualigen has been continuously advancing this sophisticated rapid diagnostic technology, which is now used in physician offices, clinics and small hospital worldwide.  I believe Qualigen is well suited to bring to market diagnostic systems that can improve our understanding and tracking of this disease as we strive to open up the U.S. economy."

    Kenneth Palmer, PhD, Director of the University of Louisville Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases (CPM), and his research team will be conducting analytical validation studies on the FastPack SARS-CoV-2 IgG Immunoassay to provide Qualigen with validation data to submit to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization. The University of Louisville's CPM is one of only 12 infectious disease biocontainment facilities in the United States and is on the forefront of COVID-19 and infectious disease research. 

    "The ability to obtain rapid, accurate SARS-CoV-2 antibody data at the point of care for timely assessment of a patient's status is vital to the next phase of this pandemic.  We are excited to be working with Qualigen on this important project," added Dr. Palmer. 

    About the FastPack System
    The FastPack System is a rapid and highly accurate immunoassay testing system consisting of the FastPack Analyzer and the FastPack test pouch (a single-use, disposable, foil packet that includes the FastPack reagent chemistry). This "Laboratory in a Pouch" is installed in physician offices, clinics and small hospitals around the world, and quickly detects diseases and medical conditions at the point-of-care.  Since the conception of the system, the Company has expanded its assay menu to 10 tests including tests for prostate cancer, thyroid function, metabolic disorders and research applications. Over the past 20 years, FastPack has generated more than $100 million in commercial sales. Qualigen's worldwide distributor for FastPack is Sekisui Diagnostics, LLC, a subsidiary of a multibillion-dollar Japanese chemical and technology company. 

    About Qualigen Therapeutics, Inc.
    Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack System, which has been used successfully in diagnostics for almost 20 years. The FastPack menu includes tests for cancer, men's health, hormone function and vitamin D status. The Company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS™. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. The foundational aptamer of ALAN, AS1411, is also being studied for use in treating viral-based infectious diseases.   RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. Qualigen's facility in Carlsbad, California is FDA and ISO Certified and its FastPack product line is sold worldwide by its commercial partner Sekisui Diagnostics, LLC. For more information on Qualigen Therapeutics, Inc. or to order FastPack diagnostic products, please visit https://www.qualigeninc.com/.   

    Forward-Looking Statements
    This news release contains forward-looking statements by the Company that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. These statements include those related to potential future development, testing and launch of product candidates. Actual events or results may differ from our expectations. For example, there can be no assurance that the validation studies for the proposed FastPack® SARS-CoV-2 IgG Immunoassay diagnostic test kits will be timely conducted or will provide favorable validation data; that any request to the FDA for Emergency Use Authorization will be granted; that the Company will be able to manufacture the FastPack Pro System instruments and test kits successfully; that any commercialization of the FastPack Pro System instruments and test kits will be profitable; that the Company will successfully develop any drugs or therapeutic devices; that preclinical or clinical development will be successful; that future clinical trial data will be favorable or that such trials will confirm any improvements over other products or lack negative impacts; that any drugs or therapeutic devices will receive required regulatory approvals or that they will be commercially successful; that we will be able to procure or earn sufficient working capital to complete the development, testing and launch of our prospective therapeutic products; or that we will be able to maintain or expand market demand and/or market share for our diagnostic products.  Our stock price could be harmed if any of the events or trends contemplated by the forward-looking statements fails to occur or is delayed or if any actual future event otherwise differs from expectations. Additional information concerning these and other risk factors affecting the Company's business (including events beyond the Company's control, such as epidemics and resulting changes) can be found in the Company's prior filings with the Securities and Exchange Commission, available at www.sec.gov.  The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

     

    Cision View original content:http://www.prnewswire.com/news-releases/qualigen-therapeutics-releases-fastpack-sars-cov-2-antibody-diagnostic-test-to-university-of-louisville-to-conduct-validation-studies-301069009.html

    SOURCE Qualigen, Inc.

    View Full Article Hide Full Article
View All Qualigen Therapeutics Inc. News